Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry have divulged EGFR (L858R/T790M/C797S triple mutant) and ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

另一方面，同源康医药所公告的试验是一项一线治疗EGFR突变肺癌脑转移的关键II期临床试验，而在肺癌治疗领域，由于现有三代EGFR-TKI药物在能否穿越血脑屏障、是否对脑转移患者有效问题上至今仍有突破空间，所以产业对在研药物的期待不小。

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of ...

LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy (CRT) (LBA4). SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with ...